SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTINewsfile Corp • 01/18/23
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 ObjectivesPRNewsWire • 01/09/23
Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022PRNewsWire • 12/12/22
Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve MyelofibrosisPRNewsWire • 12/05/22
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 96% as Wall Street Analysts Expect?Zacks Investment Research • 11/08/22
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/04/22
Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company ProgressPRNewsWire • 11/03/22
Karyopharm Announces New Selinexor Data in Myelofibrosis and Multiple Myeloma to be Presented at ASH 2022PRNewsWire • 11/03/22
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of MyelofibrosisPRNewsWire • 11/01/22
Karyopharm Therapeutics, Inc. (KPTI) CEO Richard Paulson on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company ProgressPRNewsWire • 08/04/22
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior TherapyPRNewsWire • 07/21/22
Karyopharm Granted Regulatory Designations for Eltanexor for the Treatment of Myelodysplastic SyndromesPRNewsWire • 07/20/22
Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase AgreementBenzinga • 06/15/22
Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual MeetingPRNewsWire • 05/26/22